LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 389

Search options

  1. Article ; Online: The growing clinical effect of SGLT2 inhibitors.

    Del Prato, Stefano

    The lancet. Diabetes & endocrinology

    2023  Volume 11, Issue 4, Page(s) 218–219

    MeSH term(s) Humans ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Hypoglycemic Agents
    Language English
    Publishing date 2023-03-03
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(23)00065-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Diabetes and vascular disease: New therapeutic avenues.

    Del Prato, Stefano

    Vascular pharmacology

    2023  Volume 154, Page(s) 107247

    Abstract: Vascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the ... ...

    Abstract Vascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the cardiorenal potential of medications such as glucagon-like peptide1-receptor agonists (GLP1RA) and sodium-glucose transporter 2-inhibitors (SGLT2i). Even greater are the expectations for the new dual glucose-dependent insulinotropic-peptide (GIP) and GLP1 agonists. Along with these new diabetes drugs, opportunities are now provided for renal protecting agents like finerenone. Finally, new pharmacologic venues are currently under investigation for treating diabetic cardiomyopathy, a cause for heart failure in diabetes.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Vascular Diseases/drug therapy ; Heart Failure ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/prevention & control ; Glucose
    Chemical Substances Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-11-28
    Publishing country United States
    Document type Editorial
    ZDB-ID 2082846-9
    ISSN 1879-3649 ; 1537-1891 ; 1879-3649
    ISSN (online) 1879-3649 ; 1537-1891
    ISSN 1879-3649
    DOI 10.1016/j.vph.2023.107247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 591: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Women in diabetes research: we can do better. Reply to Bonnefond A [letter].

    Mathieu, Chantal / Del Prato, Stefano

    Diabetologia

    2022  Volume 66, Issue 2, Page(s) 408–409

    MeSH term(s) Female ; Humans ; Diabetes Mellitus, Type 2
    Language English
    Publishing date 2022-11-29
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 1694-9
    ISSN 1432-0428 ; 0012-186X
    ISSN (online) 1432-0428
    ISSN 0012-186X
    DOI 10.1007/s00125-022-05840-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 279: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: Type 2 diabetes mellitus

    Del Prato, Stefano

    focus on new treatments

    (International journal of clinical practice : Supplement ; 154)

    2007  

    Author's details guest ed.: Stefano del Prato
    Series title International journal of clinical practice : Supplement ; 154
    The International journal of clinical practice
    International journal of clinical practice ; Supplement
    Collection The International journal of clinical practice
    International journal of clinical practice ; Supplement
    Language English
    Size 48 S. : graph. Darst.
    Publisher Blackwell
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT015242859
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ua VI Zs 301 -Suppl.154- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: The current landscape for diabetes treatment: Preventing diabetes-associated CV risk.

    Dardano, Angela / Bianchi, Cristina / Garofolo, Monia / Del Prato, Stefano

    Atherosclerosis

    2024  , Page(s) 117560

    Abstract: Despite the risk of atherosclerosis has progressively declined over the past few decades, subjects with type 2 diabetes mellitus (T2DM) continue to experience substantial excess of atherosclerotic cardiovascular disease (ASCVD)-related events. Therefore, ...

    Abstract Despite the risk of atherosclerosis has progressively declined over the past few decades, subjects with type 2 diabetes mellitus (T2DM) continue to experience substantial excess of atherosclerotic cardiovascular disease (ASCVD)-related events. Therefore, there is urgent need to treat ASCVD disease in T2DM earlier, more intensively, and with greater precision. Many factors concur to increase the risk of atherosclerosis, and multifactorial intervention remains the basis for effective prevention or reduction of atherosclerotic events. The role of anti-hyperglycemic medications in reducing the risk of ASCVD in subjects with T2DM has evolved over the past few years. Multiple cardiovascular outcome trials (CVOTs) with new and emerging glucose-lowering agents, namely SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1-RA), have demonstrated significant reductions of major cardiovascular events and additional benefits. This robust evidence has changed the landscape for managing people with T2DM. In addition to glycemic and ancillary extra-glycemic properties, SGLT2i and GLP1-RA might exert favorable effects on subclinical and clinical atherosclerosis. Therefore, the objective of this review is to discuss the available evidence supporting anti-atherosclerotic properties of SGLT2i and GLP1-RA, with a quick nod to sotagliflozin and tirzepatide.
    Language English
    Publishing date 2024-04-23
    Publishing country Ireland
    Document type Journal Article ; Review
    ZDB-ID 80061-2
    ISSN 1879-1484 ; 0021-9150
    ISSN (online) 1879-1484
    ISSN 0021-9150
    DOI 10.1016/j.atherosclerosis.2024.117560
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 226: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: UN resolution on diabetes "Time to put fine words into action"

    Del Prato, Stefano

    practical guidance from the global partnership for effective diabetes management to inspire and empower the diabetes community

    (International journal of clinical practice : Supplement ; 157)

    2007  

    Author's details guest ed.: Stefano Del Prato
    Series title International journal of clinical practice : Supplement ; 157
    The International journal of clinical practice
    International journal of clinical practice ; Supplement
    Collection The International journal of clinical practice
    International journal of clinical practice ; Supplement
    Language English
    Size 57 S. : Ill., graph. Darst.
    Publisher Blackwell
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT015374306
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ua VI Zs 301 -Suppl.157- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Incretins and cardiovascular disease: to the heart of type 2 diabetes?

    Solini, Anna / Tricò, Domenico / Del Prato, Stefano

    Diabetologia

    2023  Volume 66, Issue 10, Page(s) 1820–1831

    Abstract: Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide ... ...

    Abstract Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Incretins/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Cardiovascular Diseases/prevention & control ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor/agonists
    Chemical Substances Incretins ; Hypoglycemic Agents ; Glucagon-Like Peptide 1 (89750-14-1) ; Glucagon-Like Peptide-1 Receptor
    Language English
    Publishing date 2023-08-05
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1694-9
    ISSN 1432-0428 ; 0012-186X
    ISSN (online) 1432-0428
    ISSN 0012-186X
    DOI 10.1007/s00125-023-05973-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 279: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Book: Unlocking the opportunity of tight glycaemic control: inhaled insulin

    Del Prato, Stefano

    (Diabetes, obesity & metabolism ; 7, Suppl. 1)

    2005  

    Author's details guest ed.: S. del Prato
    Series title Diabetes, obesity & metabolism ; 7, Suppl. 1
    Collection
    Language English
    Size S32 S. : graph. Darst.
    Publisher Blackwell Science
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT014555117
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 5442 -7,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: How conclusive is the CONCLUDE trial?

    Del Prato, Stefano

    Diabetologia

    2020  Volume 63, Issue 4, Page(s) 692–697

    Abstract: The development of basal insulin analogues has reduced the risk of hypoglycaemia in insulin-treated individuals with type 2 diabetes. Insulin degludec and insulin glargine 300 U/ml (glargine U300) represent an evolution of basal insulin analogues, both ... ...

    Abstract The development of basal insulin analogues has reduced the risk of hypoglycaemia in insulin-treated individuals with type 2 diabetes. Insulin degludec and insulin glargine 300 U/ml (glargine U300) represent an evolution of basal insulin analogues, both of them reducing the risk of hypoglycaemia as compared with that associated with glargine U100. However, whether degludec and glargine U300 are equivalent with respect to glycaemic control and risk of hypoglycaemia remains to be fully ascertained. In the CONCLUDE trial, 1609 individuals with type 2 diabetes were randomised to either degludec 200 U/ml (degludec U200) or glargine U300. In this issue of Diabetologia (https://doi.org/10.1007/s00125-019-05080-9) the investigators report that during the maintenance period, HbA
    MeSH term(s) Blood Glucose ; Diabetes Mellitus, Type 2 ; Female ; Humans ; Hypoglycemia ; Hypoglycemic Agents ; Insulin ; Insulin Glargine ; Insulin, Long-Acting ; Male ; Reproducibility of Results
    Chemical Substances Blood Glucose ; Hypoglycemic Agents ; Insulin ; Insulin, Long-Acting ; Insulin Glargine (2ZM8CX04RZ) ; insulin degludec (54Q18076QB)
    Language English
    Publishing date 2020-01-16
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1694-9
    ISSN 1432-0428 ; 0012-186X
    ISSN (online) 1432-0428
    ISSN 0012-186X
    DOI 10.1007/s00125-020-05086-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 279: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Book ; Conference proceedings: Sulfonylureas in the therapy of type 2 diabetes: where do we stand today?

    Del Prato, Stefano

    proceedings of a symposium held on the occasion of the 41st annual meeting of the European Association for the Study of Diabetes, September 11, 2005 [Athens, Greece]

    (Metabolism ; 55,5, Suppl. 1)

    2006  

    Institution European Association for the Study of Diabetes
    Author's details Stefano Del Prato, guest ed
    Series title Metabolism ; 55,5, Suppl. 1
    Collection
    Language English
    Size S27 S. : graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT014771086
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Uc I Zs 316 -55,5,Suppl.1- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top